RayKnowChina Research Map
Shortlist0

RecruitingStomach cancerN/A

Registered title, quoted from ClinicalTrials.gov

A Multicenter, RCT Study of the Clinical Efficacy of Robotic and Laparoscopic Gastrectomy in Neoadjuvant Gastric Cancer

An open trial on stomach cancer, registered on ClinicalTrials.gov. Led by Affiliated Hospital of Qingdao University; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorAffiliated Hospital of Qingdao University青岛大学附属医院QingdaoHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06042998, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. The primary gastric lesion was diagnosed as gastric adenocarcinoma (papillary adenocarcinoma, tubular adenocarcinoma, mucinous adenocarcinoma, Signet ring cell carcinoma, poorly differentiated adenocarcinoma) by endoscopic biopsy histopathology;

    Inclusion criterion 2

  3. Before neoadjuvant treatment, the preoperative clinical staging was confirmed to be II and III (cT2N+M0 or cT3-4a/N+M0) through gastroscopy/ultrasound gastroscopy, enhanced CT/MR, or diagnostic laparoscopic exploration (based on AJCC-8th TNM tumor staging);

    Inclusion criterion 3

  4. Preoperative ECOG physical condition score of 0/1 or Karst score ≥ 70%;

    Inclusion criterion 6

  5. Have a history of other malignant diseases within 5 years;

    Exclusion criterion 7

  6. Pregnant or lactating women;

    Exclusion criterion 1

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: earlier treatment; blood tests: counts, liver and kidney function; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06042998, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • 18 years old ≤ 75 years old male or female;
  • The primary gastric lesion was diagnosed as gastric adenocarcinoma (papillary adenocarcinoma, tubular adenocarcinoma, mucinous adenocarcinoma, Signet ring cell carcinoma, poorly differentiated adenocarcinoma) by endoscopic biopsy histopathology;
  • Before neoadjuvant treatment, the preoperative clinical staging was confirmed to be II and III (cT2N+M0 or cT3-4a/N+M0) through gastroscopy/ultrasound gastroscopy, enhanced CT/MR, or diagnostic laparoscopic exploration (based on AJCC-8th TNM tumor staging);
  • 2-4 cycles of neoadjuvant therapy (chemotherapy+/- targeted/immunotherapy, simple chemotherapy);
  • After new adjuvant treatment, radical Gastrectomy is feasible after MDT discussion;
  • Preoperative ECOG physical condition score of 0/1 or Karst score ≥ 70%;
  • Preoperative ASA score I-III;
  • The expected survival period exceeds 6 months;
  • Willing and able to comply with the research protocol;
  • Sign a written informed consent form before enrollment and be fully aware of the right to withdraw from this study at any time.

Exclusion Criteria:

  • Pregnant or lactating women;
  • Suffering from serious mental illness;
  • History of upper abdominal surgery (excluding history of laparoscopic cholecystectomy);
  • History of gastric surgery (excluding ESD/EMR for gastric cancer);
  • Moderate to severe renal insufficiency;
  • Organ transplant recipients receiving immunosuppressive therapy;
  • Have a history of other malignant diseases within 5 years;
  • Have a history of unstable angina or myocardial infarction within 6 months;
  • Have a history of cerebral infarction or cerebral hemorrhage within 6 months;
  • Have a history of continuous systemic corticosteroid therapy within one month;
  • Simultaneous surgical treatment of other diseases is required (excluding laparoscopic cholecystectomy);
  • Gastric cancer comorbidities (bleeding, perforation, obstruction) requiring emergency surgery;
  • Lung function test FEV1<50% of expected value;
  • The patient has participated or is currently participating in other clinical studies (within 6 months).

Quoted from ClinicalTrials.gov, NCT06042998, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06042998, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06042998